Medical Cannabis

The partnership aims to support research, education, and patient access, aligning with both companies’ missions.

Here, we bring you our top five recent news articles, covering delays in the cannabis rescheduling hearings, DoorDash’s expansion into hemp-derived products, and more.

The internship will provide hands-on experience in medical cannabis cultivation in the country’s expanding medical cannabis market.

In response to the recent announcement that the hearing concerning cannabis rescheduling had been delayed, Americans for Safe Access held a webinar discussing the impacts medical cannabis.

Kentucky launched its medical cannabis program on January 1, 2025, allowing patients with qualifying conditions to apply for ID cards.

It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2024. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!

As we begin the year 2025, let’s review the most popular trends and topics in webinars covered by Cannabis Science and Technology in 2024.

Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.

The patient-centered organization announced its 2025 plans for medical cannabis at the national level.

The December webinar from Healer featured several studies on various conditions treated with medical cannabis.

This month’s webinar covered recent studies on cannabis use during pregnancy, CBD and anxiety, cannabis tea, and more.

On November 5, 2024, Floridians will decide on Amendment 3, which proposes legalizing recreational cannabis. Former President Trump has stated support for this measure, aligning with his stance on state-level cannabis policies.

This month’s webinar covered research on cannabis studied as a treatment for rheumatic disorders, menstrual symptoms, eczema, and more.

MM411’s president and co-founder, Chris DeVol, discusses the evolution of the company, their most popular cannabis education courses, and their partnership with Cannabis Science and Technology.

The report says that Illinois added 82 licensed dispensaries, the largest expansion of dispensaries since the program’s start in 2014.

Overall, the survey revealed that people with chronic pain supported policies expanding medical cannabis access more than physicians.

Avicanna released information on a new study through MyMedi.ca which will look into the use of medical cannabis for various health ailments such as pain, anxiety, epilepsy, sleep, and depression.

A ruling is expected this week regarding the lawsuit challenging the validity of signatures collected for two medical cannabis measures.

Panelists discussed the impacts of cannabis as a schedule 3 substance on research, legislation, patients, and more.

As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.

A recently published study found that patients using medical marijuana reported a significant increase in subjective improvements of gastrointestinal (GI) symptom severity, compared to not using medical marijuana.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

The majority of comments on the scheduling of cannabis favored change, though several other aspects of cannabis policy remain to be addressed.

Tilray’s Aphria RX obtained a cannabis trading license recently in Germany.

California’s bill creating new restrictions on intoxicating hemp products has prompted responses citing negative impacts on patients and businesses.